1. Maloum, Karim, Settegrana, Catherine, Chapiro, Elise, Davi, Frederic, Merle-Béral, Hélène. 2009. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. In Annals of hematology, 88, 1215-21. doi:10.1007/s00277-009-0742-6. https://pubmed.ncbi.nlm.nih.gov/19340428/
2. Zhao, Meng, Jia, Wang, Jiang, Wen G, Cheng, Shan, Song, Maomin. . ADAM29 Expression in Human Breast Cancer and its Effects on Breast Cancer Cells In Vitro. In Anticancer research, 36, 1251-8. doi:. https://pubmed.ncbi.nlm.nih.gov/26977022/
3. Wei, Xiaomu, Moncada-Pazos, Angela, Cal, Santiago, López-Otín, Carlos, Samuels, Yardena. 2011. Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma. In Human mutation, 32, E2148-75. doi:10.1002/humu.21477. https://pubmed.ncbi.nlm.nih.gov/21618342/
4. Wang, Tingting, Lv, Xiaoyan, Jiang, Shen, Han, Shaorong, Wang, Yanming. 2020. Expression of ADAM29 and FAM135B in the pathological evolution from normal esophageal epithelium to esophageal cancer: Their differences and clinical significance. In Oncology letters, 19, 1727-1734. doi:10.3892/ol.2020.11272. https://pubmed.ncbi.nlm.nih.gov/32194665/
5. Oppezzo, Pablo, Vasconcelos, Yuri, Settegrana, Catherine, Dighiero, Guillaume, Davi, Frédéric. 2005. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. In Blood, 106, 650-7. doi:. https://pubmed.ncbi.nlm.nih.gov/15802535/
智鼠故事 
